Findings

What do systematic reviews say?

5 questions · 11 findings · 4 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

No studies found 6 · 54.5%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 9.1%High 4 · 36.4%

Progression‐free survival · high‐grade glioma

The review found no eligible studies for this question.

2 findings from 2 reviews · compare the 2 reviews

Intraoperative imaging technology to maximise extent of resection for glioma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Intraoperative imaging technology to maximise extent of resection for glioma 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Progression‐free survival · high‐grade glioma

The review found no eligible studies for this question.

2 findings from 2 reviews · compare the 2 reviews

Intraoperative imaging technology to maximise extent of resection for glioma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Intraoperative imaging technology to maximise extent of resection for glioma 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Progression‐free survival · high‐grade glioma

The review found no eligible studies for this question.

2 findings from 2 reviews · compare the 2 reviews

Intraoperative imaging technology to maximise extent of resection for glioma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Intraoperative imaging technology to maximise extent of resection for glioma 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Progression‐free survival · people with non‐rhabdomyosarcoma soft tissue sarcoma

The intervention showed no clear difference in progression‐free survival (high certainty).

1 finding from 1 review

Progression‐free survival · people with HGG

Anti‐angiogenic therapy leads to lower progression‐free survival ( compared with no anti‐angiogenic therapy (high certainty).

4 findings from 1 review

Anti‐angiogenic therapy for high‐grade glioma 2018 · Cochrane Headline outcomes only
HR 0.73 [0.68, 0.79]
10 studies · 3595 participants
High
Anti‐angiogenic therapy for high‐grade glioma 2018 · Cochrane Headline outcomes only
HR 0.75 [0.69, 0.82]
8 studies · 2833 participants
High
Anti‐angiogenic therapy for high‐grade glioma 2018 · Cochrane Headline outcomes only
HR 0.64 [0.54, 0.76]
2 studies · 762 participants
Moderate

Show 1 more finding

Anti‐angiogenic therapy for high‐grade glioma 2018 · Cochrane Headline outcomes only
HR 0.72 [0.66, 0.77]
10 studies · 3464 participants
High